NanoString commences second clinical study of PAM50-based breast cancer assay

[News]

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced the initiation of the second clinical validation study of its PAM50-based breast cancer assay.

More... (http://www.news-medical.net/news/20120517/NanoString-commences-second-clinical-study-of-PAM50-based-breast-cancer-assay.aspx)